{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026346","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2022-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.531057+00:00","generated_at":"2026-06-21T06:20:03.431878+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SAB Biotherapeutics raises ~$7.9M in private placement of common stock and warrants","bullets":["Gross proceeds ~$7.9M from sale of ~7.36M shares and warrants at $1.08 per unit.","Warrants exercisable after 6 months at $1.08/share, expire in 5 years.","Proceeds to advance C. diff and type 1 diabetes pipeline and for working capital.","Existing investors including T. Denny Sanford and new institutional investors participated.","Brookline Capital Markets acted as exclusive placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026346","json":"https://secwatch.observer/filing/0000950170-22-026346.json","markdown":"https://secwatch.observer/filing/0000950170-22-026346.md","text":"https://secwatch.observer/filing/0000950170-22-026346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017022026346/0000950170-22-026346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017022026346/sabs-20221206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T06:20:03.431878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a6dbc49f4bbdeb5eef3076b0e04d43445f1c7d2","claim":"SAB Biotherapeutics, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $8.0 million (effective 2022-12-06).","evidence_excerpt":"On December 6, 2022, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017022026346/0000950170-22-026346-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $8.0 million"},{"label":"Effective","value":"2022-12-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}